These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 4471640

  • 1. Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.
    Sparks FC, Breeding JH.
    Cancer Res; 1974 Dec; 34(12):3262-9. PubMed ID: 4471640
    [No Abstract] [Full Text] [Related]

  • 2. Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.
    Simmons RL, Rios A.
    Natl Cancer Inst Monogr; 1973 Dec; 39():57-68. PubMed ID: 4595327
    [No Abstract] [Full Text] [Related]

  • 3. Immuno-therapy of methyl cholanthrene induced and spontaneous tumors in mice by use of tumor vaccine, neuraminidase and BCG.
    Gautam S, Aikat BK.
    Indian J Med Res; 1976 Mar; 64(3):472-81. PubMed ID: 965048
    [No Abstract] [Full Text] [Related]

  • 4. Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guérin and tumor cells.
    Zbar B, Canti G, Rapp HJ, Ashley MP, Sukumar S, Bast RC.
    Cancer Res; 1980 Apr; 40(4):1036-42. PubMed ID: 7357533
    [No Abstract] [Full Text] [Related]

  • 5. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
    Liotta LA, Kleinerman J, Saidel GM.
    Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897
    [Abstract] [Full Text] [Related]

  • 6. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC, Silverstein MJ, Hunt JS, O'Connell TX, Lee YT, Pilch YH, Haskell CM, Morton DL.
    Johns Hopkins Med J Suppl; 1974 Sep; 3():103-20. PubMed ID: 4609024
    [No Abstract] [Full Text] [Related]

  • 7. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
    Simmons RL, Rios A.
    Johns Hopkins Med J Suppl; 1974 Sep; 3():75-84. PubMed ID: 4536589
    [No Abstract] [Full Text] [Related]

  • 8. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J.
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [Abstract] [Full Text] [Related]

  • 9. Toxicity of intrapleural Bacillus Calmette-Guérin treatment in animals.
    Filardi MJ, Codish SD, Civerchia L, Howard RK, McKneally MF.
    Cancer Res; 1979 Sep; 39(9):3673-6. PubMed ID: 383285
    [Abstract] [Full Text] [Related]

  • 10. Comparative immunotherapeutic effect of concanavalin A and neuraminidase-treated cancer cells.
    Simmons RL, Rios A.
    Transplant Proc; 1975 Jun; 7(2):247-51. PubMed ID: 1129845
    [No Abstract] [Full Text] [Related]

  • 11. Influence of surfactant concentration on the antitumor activity of emulsified components of mycobacteria.
    Yarkoni E, Rapp HJ.
    Cancer Res; 1980 Apr; 40(4):975-8. PubMed ID: 7357563
    [Abstract] [Full Text] [Related]

  • 12. Suppression of transplanted rat sarcomata mediated by Bacillus Calmette Guéin (BCG).
    Moore M, Lawrence N, Witherow PJ.
    Eur J Cancer (1965); 1974 Oct; 10(10):673-82. PubMed ID: 4533899
    [No Abstract] [Full Text] [Related]

  • 13. Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria.
    Yarkoni E, Rapp HJ.
    Cancer Res; 1979 Feb; 39(2 Pt 1):535-7. PubMed ID: 761228
    [Abstract] [Full Text] [Related]

  • 14. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice.
    Lynch NR, Salomon JC.
    J Natl Cancer Inst; 1979 Jan; 62(1):117-21. PubMed ID: 281566
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
    Yron I, Weiss DW, Robinson E, Cohen D, Adelberg MG, Mekori T, Haber M.
    Natl Cancer Inst Monogr; 1973 Dec; 39():33-55. PubMed ID: 4362523
    [No Abstract] [Full Text] [Related]

  • 16. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.
    Bennett JA, Gruft H, McKneally MF, Zelterman D, Crispen RG.
    Cancer Res; 1983 Sep; 43(9):4183-90. PubMed ID: 6347367
    [Abstract] [Full Text] [Related]

  • 17. Corynebacterium-induced protection against artificial pulmonary metastases of a syngeneic fibrosarcoma in mice.
    Milas L, Hunter N, Withers HR.
    Cancer Res; 1974 Mar; 34(3):613-20. PubMed ID: 4590922
    [No Abstract] [Full Text] [Related]

  • 18. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL, Rios A.
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract] [Full Text] [Related]

  • 19. Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
    Simmons RL, Rios A, Lundgren G, Ray PK, McKhann CF, Haywood GR.
    Surgery; 1971 Jul; 70(1):38-46. PubMed ID: 5092115
    [No Abstract] [Full Text] [Related]

  • 20. Studies of the effects of Bacillus Calmette-Guérin on Moloney sarcoma virus-induced tumors in normal and immunosuppressed mice.
    Houchens DP, Goldberg AI, Gaston MR, Kende M, Goldin A.
    Cancer Res; 1973 Apr; 33(4):685-90. PubMed ID: 4696469
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.